Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 22, Number 3—March 2016

Online Report

Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis

Jennifer FurinComments to Author , Grania Brigden, Erica Lessem, Michael Rich, Laura Vaughan, and Sharonann Lynch
Author affiliations: Harvard Medical School, Boston, Massachusettes, USA (J. Furin); Médecins Sans Frontières Access Campaign, Geneva, Switzerland (G. Brigden, S. Lynch); Treatment Action Group, New York, NY, USA (E. Lessem); Brigham and Women’s Hospital, Boston (M. Rich); Partners In Health, Boston (M. Rich, L. Vaughan)

Main Article

Table 4

World Health Organization–defined high-burden, low- and middle-income countries using or waiting for drug arrival to begin using bedaquiline under program conditions for treatment of multidrug-resistant tuberculosis

Currently using Awaiting drug arrival
Armenia Bangladesh
Belarus Bolivia
Georgia Brazil
Indonesia Cameroon
Lesotho Cote d’Ivoire
Papua New Guinea North Korea
Russia Democratic Republic of the Congo
South Africa Ethiopia
Swaziland India
Kazakhstan
Kenya
Kyrgyzstan
Mozambique
Myanmar
Namibia
Nigeria
Peru
Philippines
South Korea
Thailand
Turkmenistan
United Republic of Tanzania
Uzbekistan
Vietnam

Main Article

TOP